BG103306A - Liquid allendronate compositions - Google Patents

Liquid allendronate compositions

Info

Publication number
BG103306A
BG103306A BG103306A BG10330699A BG103306A BG 103306 A BG103306 A BG 103306A BG 103306 A BG103306 A BG 103306A BG 10330699 A BG10330699 A BG 10330699A BG 103306 A BG103306 A BG 103306A
Authority
BG
Bulgaria
Prior art keywords
allendronate
compositions
liquid
composition
value
Prior art date
Application number
BG103306A
Other languages
Bulgarian (bg)
Inventor
Maneesh NERURKAR
William Hunke
Drazen Ostovic
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700541.7A external-priority patent/GB9700541D0/en
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG103306A publication Critical patent/BG103306A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

The invention relates to a composition of allendronic acid or its pharmaceutically acceptable salt containing sufficient buffer so that its pH value will be from 4 to 7.5 and 15 ml of the composition can increase the pH value of 50 ml 0.1 N HCl from 1 to at least 3, preferably to 4. 17 claims
BG103306A 1996-10-04 1999-04-02 Liquid allendronate compositions BG103306A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2676596P 1996-10-04 1996-10-04
GBGB9700541.7A GB9700541D0 (en) 1997-01-13 1997-01-13 Liquid alendronate formulation
US3600297P 1997-01-22 1997-01-22
PCT/US1997/015740 WO1998014196A1 (en) 1996-10-04 1997-10-02 Liquid alendronate formulations

Publications (1)

Publication Number Publication Date
BG103306A true BG103306A (en) 2000-01-31

Family

ID=27268667

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103306A BG103306A (en) 1996-10-04 1999-04-02 Liquid allendronate compositions

Country Status (20)

Country Link
EP (1) EP1007054A4 (en)
JP (1) JP2001501222A (en)
CN (1) CN1238691A (en)
AU (1) AU723357B2 (en)
BG (1) BG103306A (en)
BR (1) BR9712197A (en)
CA (1) CA2267370A1 (en)
CZ (1) CZ116999A3 (en)
EA (1) EA001213B1 (en)
EE (1) EE03669B1 (en)
HU (1) HUP0000125A3 (en)
IL (1) IL129127A0 (en)
IS (1) IS5012A (en)
NO (1) NO991569L (en)
NZ (1) NZ334836A (en)
PL (1) PL332496A1 (en)
SK (1) SK42999A3 (en)
TR (1) TR199900730T2 (en)
WO (1) WO1998014196A1 (en)
YU (1) YU17499A (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60111574T2 (en) 2001-01-23 2006-05-11 Gador S.A. Bisphosphonate-containing compositions for the prevention and / or cure of metabolic bone diseases, methods for their preparation and use of these compositions
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
CA2622322A1 (en) * 2005-09-16 2007-03-22 Selamine Ltd Bisphosphonate formulation
JP2010043119A (en) * 2009-10-16 2010-02-25 Gador Sa Composition for preventing and/or treating bone metabolic disease, method of preparing the same and use thereof
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
IT1201087B (en) * 1982-04-15 1989-01-27 Gentili Ist Spa PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (en) * 1993-04-05 1995-06-30 Sanofi Elf USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR PROMOTING BONE REPAIR.
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Also Published As

Publication number Publication date
BR9712197A (en) 1999-08-31
NO991569D0 (en) 1999-03-30
YU17499A (en) 1999-11-22
CA2267370A1 (en) 1998-04-09
PL332496A1 (en) 1999-09-13
NO991569L (en) 1999-06-04
EE03669B1 (en) 2002-04-15
IS5012A (en) 1999-03-26
NZ334836A (en) 2000-11-24
CZ116999A3 (en) 1999-09-15
EA199900352A1 (en) 1999-08-26
AU4644897A (en) 1998-04-24
AU723357B2 (en) 2000-08-24
EE9900113A (en) 1999-10-15
CN1238691A (en) 1999-12-15
HUP0000125A2 (en) 2000-06-28
WO1998014196A1 (en) 1998-04-09
EP1007054A4 (en) 2000-07-19
SK42999A3 (en) 2000-01-18
TR199900730T2 (en) 1999-07-21
HUP0000125A3 (en) 2001-04-28
JP2001501222A (en) 2001-01-30
IL129127A0 (en) 2000-02-17
EP1007054A1 (en) 2000-06-14
EA001213B1 (en) 2000-12-25

Similar Documents

Publication Publication Date Title
BG103930A (en) Eletriptan hemisulphate and caffeine containing pharmaceutical compositions
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
NO944164L (en) Process for the preparation and use of an HCl adsorbent
MY120984A (en) Activated protein c formulations
BG102259A (en) Compostions with controlled paroxetine release
NZ279397A (en) Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives and pharmaceutucal compositions
NZ514330A (en) Zinc containing dentifrice compositions
ES2160949T3 (en) DERIVATIVES OF PHENYLENE-SULFONAMIDE REPLACED IN META.
DE69705300T2 (en) CYCLOPROPYLALKANSÄUREDERIVATE
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
JO2034B1 (en) LH-RH peptide analogues, their uses and pharmaceutical compositions containing them
EP0656030A4 (en) Stabilizer system for thiol-ene and thiol-nene compositions.
IL109720A (en) N-alkylthio polyamine derivatives and radioprotective compositions containing them
EP0831871A4 (en) Relaxin-like factor and methods and uses thereof
BG103306A (en) Liquid allendronate compositions
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
WO2001010408A3 (en) Aqueous pharmaceutical composition containing moxifloxacin or salts thereof
WO1999006388A3 (en) Pharmaceutical compounds isolated from aristolochia taliscana
WO1996022305A3 (en) Modified peptides
NZ337798A (en) Pharmaceutical compositions containing lamivudine
CA2047802A1 (en) Pharmaceutical compositions
UA42722C2 (en) Sulphides, sulphoxides and sulphones or the pharmaceutically acceptable salts thereof and pharmaceutical composition containing them
BG103412A (en) Stabilized pharmaceutical compositions based on chinupristine and dalfopristine and their preparation
ZA934777B (en) Novel piperidyl amides, sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis.